RxDoctor Payments Data

Stephen Bergquist, MD

Internal Medicine · Jackson, TNNPI 1992896401

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,000 of the $25,286 with a category attached, or 83.0%. Mimedx Group, Inc. accounts for 92.6% of it on its own, with 19 other manufacturers making up the rest. Among internal medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,286in general payments, 2019–2025

Across 85 payments — averaging $297.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mimedx Group, Inc.$23K
  • Smith+Nephew$456
  • Polymedics Innovations Inc.$224
  • Medline Industries LP$218
  • Kerecis Limited$173
  • Convatec Inc.$107
  • plus $703 from 14 others

What the payments were for

  • Speaking & faculty fees$21,00083%
  • Travel & lodging$2,2519%
  • Food & beverage$2,0368%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$25,286 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$113,096
Medicare patients
213
Services billed
1,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.12$65,553
Fluconazole43$576
Doxycycline Hyclate59$560
SsdSilver Sulfadiazine13$356
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$278
Ketoconazole15$276
Cefdinir22$264
Levofloxacin58$224
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim35$157
Mupirocin11$142
Ciprofloxacin Hcl22$122
Amoxicillin17$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$456$65,55312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Jackson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →